A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol - ROCKET II- Randomized Open Label Switch for Cholesterol Elevation on Kivexa+Kaletra Evaluation Trial
- Conditions
- Adult HIV-1 infected subjects on a stable HAART regimen of Kivexa + Kaletra, with raised cholesterolMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1
- Registration Number
- EUCTR2008-002043-16-AT
- Lead Sponsor
- Gilead Sciences Europe Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 160
Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
• = 18 years old
• Plasma HIV 1 RNA < 50 copies/mL at Screening and = 12 weeks prior to Screening
• Stable HAART regimen of Kivexa + Kaletra for = 24 weeks prior to Screening
• Documented confirmed raised total cholesterol = 5.2 mmol/L (= 200 mg/dL) for the last two consecutive tests (at least 4 weeks apart) with the last result = 4 weeks prior to Screening
• Fasted total cholesterol = 5.2 mmol/L (= 200 mg/dL) at Screening
• Subject willing to continue current unmodified HAART for 12 weeks if randomized to Group 2
• Subjects requiring concomitant lipid regulating therapy must be established on a stable dose/frequency = 12 weeks prior to Screening and be expected to remain stable in dose and frequency throughout the treatment phase of the study
• Adequate renal function by calculated creatinine clearance = 60 mL/min according to the Cockcroft–Gault formula
• Negative serum pregnancy test (females of childbearing potential only i.e., not surgically sterile or at least 2 years post-menopausal)
• Serum Total Bilirubin = 1.5 mg/dL
Women of childbearing potential (WOCBP) must be using a highly effective method of contraception to avoid pregnancy throughout the study and for up to 30 days after the last dose of study drugs in such a manner that the risk of pregnancy is minimized – refer to Section 7.8 for the definition of highly effective method of birth control.
• Female subjects who are postmenopausal for less than 2 years are required to have follicle stimulating hormone (FSH) = 40 mIU/mL. If the FSH is < 40 mIU/mL, the subject must agree to use highly effective method of birth control to participate in the study– refer to Section 7.8 for the definition of highly effective method of birth control.
• Male subjects who are sexually active must be willing to use effective barrier contraception (e.g. condom with spermicide) during heterosexual intercourse from screening through completion of the study and continuing for up to 30 days after the last dose of study drugs
• Life expectancy = 1 year
• The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
• Pregnant or lactating subjects
• Previous treatment with emtricitabine (FTC), tenofovir DF (TDF) or adefovir dipivoxil (ADV)
• Known hypersensitivity to emtricitabine (FTC), tenofovir DF (TDF), Truvada or any of the excipients (e.g., lactose monohydrate, see 5.2.1)
• Documented resistance to any of the study drugs (either genotypic or phenotypic)
• Severe hepatic impairment
• Hepatitis B infection with viral load > 1.000 copies/ml at Screening or Hepatitis C infection requiring therapy.
• Treatment with any interferon or pegylated interferon within 18 months prior to Screening.
• Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) = 5 × upper limit of normal (ULN)
• Subjects receiving ongoing therapy with any of the medications that are contraindicated with any of the study drugs. Administration of any of these medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period. The full list of disallowed medications can be found in Appendix 5 of the protocol.
• Active, serious infections (other than HIV infection) requiring parenteral antibiotic therapy within 15 days prior to screening
• Prior history of significant renal or bone disease
• Any current known clinical or symptomatic laboratory parameter of GSI Grade 4 (see Appendix 4). Asymptomatic Grade 4 abnormalities will be permitted at the discretion of the investigator if deemed clinically appropriate (excluding adverse events and laboratory parameters mentioned elsewhere in the inclusion/exclusion criteria). Abnormalities deemed insignificant by the investigator must be discussed with the Medical Monitor prior to enrollment.
• Malignancy other than cutaneous Kaposi sarcoma (KS) or basal cell carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of baseline and are not anticipated to require systemic therapy during the study
• Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance
• Subjects currently taking part in any other clinical trial using an investigational product, with the exception of studies where the treatment studied has been stopped for more than 1 month prior to baseline
• Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To determine if switching the NRTI backbone from a Kivexa to Truvada leads to a reduction in fasting total cholesterol at 12 weeks.;Primary end point(s): The primary efficacy endpoint is change from baseline in total cholesterol at Week 12.;Secondary Objective: • Evaluation of fasting metabolic parameters (e.g., LDL, HDL, non-HDL cholesterol, triglycerides, and cholesterol ratios).<br>• Evaluation of efficacy and safety by assessing adverse events, clinical laboratory tests, physical examinations and vital signs at every visit.<br>• Evaluation of changes in the 10-year risk factor for coronary heart disease outcomes as measured by total cholesterol, HDL, blood pressure, smoking status, treatment for hypertension, sex and age.
- Secondary Outcome Measures
Name Time Method